

PRESS RELEASE

Novelogs Biotechnology Inc. receives Government of Canada support for the development of new cancer treatment

VANCOUVER, BC- August 7, 2013 – Novelogs Biotechnology Inc. announced today that it has received a financial contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) of up to \$50,000 to aid in the development of Novelogs' new approach to fighting cancer. The objective of the cancer treatment project is to complete a proof-of-concept study that validates the approach by mid-2014.

The proprietary technology behind Novelogs' innovation involves discovery and development of monoclonal antibodies that target an undisclosed protein that is involved with the undesirable immune system suppression associated with cancer. It is predicted that this new therapy will broadly treat many types of cancers and will do so in a less toxic fashion with fewer debilitating side-effects. Patients should not get sick to get better, as it stimulates the body's own immune system to fight cancer more naturally.

NRC-IRAP's ongoing technical and business advice, along with its financial contribution, is helping to guide and optimize the overall research endeavour in a timely fashion. It is anticipated that a lead development candidate antibody will be selected in 2014, which will not only help validate our concept but also justify our drive towards cancer clinical trials.

About Novelogs Biotechnology Inc.

Novelogs Biotechnology Inc. is an early-stage life sciences company dedicated to developing innovative cancer treatments that harness the power of the immune system to help eradicate tumors more naturally. Our immunotherapy concepts focus on development of antibody therapeutics and medical devices and are designed to treat multiple cancer types and to have fewer side effects than traditional cancer therapies. We anticipate the technology will be well received by larger biotechnology and pharmaceutical companies that are interested in commercializing new treatments in this exciting area of cancer drug development. Novelogs has one mission in mind. We want to create better cancer treatments. <http://novelogs.com>

Novelogs Biotechnology Inc. is a privately-owned corporation operating in Vancouver, Canada.

Media contact:

Elaine Allison

info@novelogs.com

(604) 723-7774